Loading…
Loading…
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. ("DaVita" or the "Company") (NYSE: DVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on profitability.
Nearly 1,000 people screened in Houston and Los Angeles, with a majority showing signs of elevated chronic disease risk DENVER, Oct. 27, 2026 /PRNewswire/ -- Millions of Americans are living with chronic disease and don't know it. The risks are often interconnected: High blood pressure and diabetes can increase the risk of kidney disease, while chronic kidney disease (CKD) often progresses without symptoms.
DaVita HealthCare (DVA) closed at $183.64 in the latest trading session, marking a -1.32% move from the prior day.
DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.
CWA Asset Management Group LLC grew its stake in DaVita Inc. (NYSE: DVA) by 15.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,064 shares of the company's stock after purchasing an additional 3,574 shares during the period. CWA Asset
DENVER, Oct. 19, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2026, at 5:00 p.m. Eastern Time.